Anti-GM-CSF antibodies and uses therefor

Details Anti-GM-CSF antibodies and uses therefor Anti-GM-CSF antibodies and uses therefor

2011-01-11

2011-01-11

Mertz, Prema (Department: 1646)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C530S387100, C530S388100, C530S388230, C530S388150, C530S387300

Reexamination Certificate

active

07867495

ABSTRACT:
The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

REFERENCES:
patent: 5747032 (1998-05-01), Metcalf et al.
patent: 6300064 (2001-10-01), Knappik et al.
patent: 7427401 (2008-09-01), Lopez et al.
patent: WO 97/08320 (1997-03-01), None
patent: WO 03/068920 (2003-08-01), None
Alvaro-Gracia et al., “Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-α,” J Immunol., May 15, 1991, 146(10):3365-3371.
Babior, B., “Phagocytes and oxidative stress,” Am. J. Med., Jul. 2000, 109:33-44.
Bonfield et al., “Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis,” Clin. Immunol., Dec. 2002, 105(3):342-350.
Bozinovski et al., “Innate immune responses to lipopolysaccharide in mouse lung are suppressed and reversed by neutralization of GM-CSF via repression of TLR-4,” Am. J. Physiol. Lung Cell Mol. Physiol., 2004, 286:L877-L885.
Broide et al., “Endobronchial allergen challenge in asthma. Demonstration of cellular source of granulocyte macrophage colony-stimulating factor by in situ hybridization,” J. Clin. Invest., Sep. 1991, 88:1048-1053.
Broide et al., “Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics,” J. Clin. Invest., Oct. 1992, 90:1414-1424.
Brown et al., “Mapping of human granulocyte-macrophage-colony-stimulating-factor domains interacting with the human granulocyte-macrophage-colony-stimulating-factor-receptor alpha-subunit,” Eur. J. Biochem., 1994, 225:873-880.
Burmester et al., “Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis?” Arthritis & Rheumatism, Jan. 1997, 40(1)5-18.
Campbell et al., “Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice,” Ann. Rheum. Dis., 1997, 56:364-368.
Campbell et al., “Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice,” J. Immunol., 1998, 161:3639-3644.
Carrieri et al., “Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity,” Immunopharmacol. Immunotoxicol., 1998, 20(3):373-382.
Cebon et al., “Granulocyte-macrophage stimulating factor from human lymphocytes,” J. Biol. Chem., Mar. 15, 1990, 265(8):4483-4491.
Chantry et al,. “Granulocyte-macrophage colony stimulating factor induces both HLA-DR expression and cytokine production by human monocytes,” Cytokine, Jan. 1990, 2(1):60-67.
Chen et al., “Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen,” J. Mol. Biol. , 1999, 293:865-81.
Cheng et al., “Granulocyte-macrophage colony stimulating factor up-regulates CCR1 in human neutrophils,” J. Immunol., 2001, 166:1178-1184.
Clark et al., “The human hematopoietic colony-stimulating factors,” Science, Jun. 5, 1987, 236:1229-1237.
Cook et al., “Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease,” Arthritis Research, 2001, 3:293-298.
de Groot et al., “Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family,” Cell. Signal, 1998, 10(9):619-628.
de Vries et al., “Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy,” Lancet, Aug. 24, 1991, 338:517-518.
Diederichs et al., “Novel fold and putative receptor binding site of granulocyte-macrophage colony-stimulating factor,” Science, Dec. 20, 1991, 254:1779-1782.
Drake et al., “Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods,” Anal. Biochem. 2004, 328:35-43.
Dranoff et al., “Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis,” Science, Apr. 29, 1994, 264:713-716.
Friguet et al., “Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay,” J. Immunol. Methods, 1985, 77:305-19.
Gasson et al., “Human granulocyte-macrophage colony-stimulating factor (GM-CSF): regulation of expression,” Hematopoietic Growth Factors in Transfusion Medicine, 1990:27-41.
Gasson et al., “The biology of human granulocyte-macrophage colony-stimulating factor (GM-CSF),” The Biology of Hematopoieses, 1990:375-384.
Gasson et al., “High-affinity binding of granulocyte-macrophage colony-stimulating factor to normal and leukemic human myeloid cells,” Proc .Natl .Acad. Sci. U S A., Feb. 1986, 83:669-673.
Gearing et al., “Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor,” EMBO J., 1989, 8(12):3667-3676.
Gomez-Cambronero et al., “Granulocyte-macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: involvement of the ribosomal p70 S6 kinase signaling pathway,” J. Immunol., 2003, 171:6846-6855.
Grossman, H.B., “Clinical Applications of Monoclonal Antibody Technology,” Urologic Clinics of North America, Aug. 1986, 13(3):465-474.
Haenel et al., “Characterization of high-affinity antibodies by electrochemiluminescence-based equilibrium titration,” Analytical Biochemistry, 2005, 339(1):182-184.
Hamilton,J.A., “Rheumatoid arthritis: opposing actions of hemopoietic growth factors and slow acting anti-rheumatic drugs,” Lancet, Aug. 28, 1993, 342:536-539.
Hamilton,J.A., “GM-CSF in inflammation and autoimmunity,” Trends Immunol., Aug. 2002, 23(8):403-408.
Hart et al., “Synergistic activation of human monocytes by granulocyte-macrophage colony-stimulating factor and IFN-gamma. Increased TNF-alpha but not IL-1 activity,” J. Immunol., Sep. 1, 1998, 141(5):1516-1521.
Haworth et al., “Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α,” Eur. J. Immunol., 1991, 21:2575-2579.
Hayashida et al., “Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor,” Proc. Natl. Acad. Sci. U S A, Dec. 1990, 87:9655-9659.
Hazenberg et al., “Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis,” Blood, Dec. 1989, 74(8):2769-2780.
Kastelein et al., “GM-CSF receptor: interactions and activiation,” Oncogene, 1993, 8:231-236.
Kaufman et al., “Effects of human GM-CSF on neutrophil degranulation in vitro,” Exp. Hematol., 1989, 17:800-804.
Khaw et al., “Myocardial Infarct Imaging of Antibodies to Canine Cardiac Myosin with Indium-111-Diethylenetriamine Pentaacetic Acid,” Science, Jul. 11, 1980, 208

Affiliated with

Also associated with

Rating

Anti-GM-CSF antibodies and uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-GM-CSF antibodies and uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-GM-CSF antibodies and uses therefor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2646929